

Antagonistic Effect of Lactobacillus Fermentum Supernatant Against Enterococcus Faecium and Enterococcus Faecalis In Vitro

Likaa H. Mahdi*
Sanaa N. Husain*

BSc,MSc,PhD,
BSc,MSc,PhD,

Summary:

Background: Lactobacillus fermentum selected as an alternative treatment to prevent or treat urogenital infection based on their probiotics properties and production of bacteriocins.

Objective: The present work was done to study the inhibition activity of L. fermentum cell free supernatant against urogenital pathogens Enterococcus faecium and Enterococcus faecalis in vitro.

Materials and methods: L. fermentum isolates have been collected from vaginal swabs. A supernatant of these isolates has been prepared and its antibacterial activity against 3 isolates of E. faecium and 3 isolates of E. faecalis has been studied.

Results: Different concentrations have been prepared and the most effective one was 1000 µg/ml and the most affected isolate of E. faecalis was no. 3 which its MIC was 64 µg/ml and MBC was 128 µg/ml, while the most affected isolate of E. faecium was no. 1 which its MIC was 128 µg/ml and MBC was 256 µg/ml.

Conclusion: L. fermentum CFS showed significant activity against both Enterococcus isolates and showed closely related results.

Keywords: Lactobacillus fermentum, Antibacterial activity, Antagonistic effect, Enterococcus faecium, Enterococcus faecalis, vaginosis.

Fac Med Baghdad
2012; Vol. 54, No.2
Received Feb, 2012
Accepted May, 2012

Introduction:

Lactobacillus group are the dominant microorganisms in healthy pre-menopausal women and play an important protective role by limiting growth of pathogenic microorganisms (1). Lactobacillus are able to interfere with genitourinary pathogens by several mechanisms including competitive exclusion from the cell surface, production of adhesion inhibiting bio surfactant compounds, auto aggregation surface, hydrophobicity and co-aggregation with other bacterial species (2). Many reports show the usefulness of lactic acid bacteria (LAB) as probiotics for humans and animals (3). Appealing properties of probiotics include the ability to reduce antibiotic use, the apparently high index of safety, and the public's positive perception about <natural> or <alternative> therapies. Potential probiotic bacteria are classified, and generally regarded as safe as opposed to antibiotics, which have a number of recognized adverse effects (4). They can be used as natural competitive micro biota or as specific starter cultures under controlled conditions (5). The promotion of immune system maturation and defense against infections as well as the anti-inflammatory properties are among the main healthy effects of these bacteria (6). Therefore, without education and good products, it is not surprising that family physicians barely use probiotics in their practices (7). So we aimed in this research to study the antagonistic effect of L. fermentum against urogenital pathogens E. faecium and E. faecalis.

Materials and methods:

Bacterial isolates: Nine L. fermentum isolates have been collected from vaginal swabs of healthy women their age ranged between 18-45 years old at AL-Yarmouk Hospital and the research was done at Ministry of Science and Technology and Department of Biology at College of Science / AL-Mustansiriyah University. The samples were inoculated in MRS broth and incubated at 37°C for 48 h. under anaerobic condition, and the growth cultures were plated on MRS agar at the same condition, the identity of the cultures was based on the characteristics of the lactobacilli such as cultural, microscopically and biochemical characters which included fermentation of different carbon sources, gas production from glucose, growth at different temperatures, tolerance to inhibiting substances such as bile (Sigma), phenol (Merck) and sodium chloride (biotech) as described by (8,9), then the pure cultures were maintained on MRS agar. Uropathogenic microorganisms included three isolates of E. faecium and three isolates of E. faecalis isolated from urine were employed to study the antagonistic effect of L. fermentum against them.

Preparation of cell free supernatants (CFSs): An overnight culture of L. fermentum isolates were adjusted with MRS broth in accordance to McFarland turbidity standard solution no.5 as measured by absorbance (0.08-0.1 at 625 nm) corresponding to approximately 1.5-2 × 10⁸ CFU/ml. Afterward, the cultures were propagated in the same broth at 37°C for 24h under anaerobic condition. Bacterial cells were removed by centrifugation of the cultures at 6000 rpm / 10min

*Dept. of Biology - College of Science - Al Mustansiriyah University

at 4°C. The resulting supernatants filtered through sterilized 0.22 µm filter paper then cultured on MRS agar in order to confirm the absence of lactobacilli cells. The supernatants were concentrated by ammonium sulphate precipitation (700 g/L). After the mixtures had been stirred overnight at 4°C, the precipitates were pelleted by centrifugation at 10,000 rpm / 30min. Then, the collected precipitates were dissolved in 0.05 M sodium acetate buffer pH 5.0 and dialyzed against the same buffer at 4°C overnight (10). Protein concentration after each purification step was determined(11) and the activity unit per ml (Au/mg) was assayed(12). The putative metabolites produced by *L.fermentum* isolates were lyophilized and dissolved in phosphate buffered saline (2mM Na₂HPO₄, 0.5mM KH₂PO₄, 1.3mM KCl, 135mM NaCl, pH 7.0) for prepare different concentrations (13).

Antimicrobial activity assay:

1) Agar well diffusion method: This method was used to detect antimicrobial activity of CFS_s produced by *L.fermentum* against *Enterococcus* isolates at different concentrations (1000, 750, 500, 250) µg/ml according to Batdorj et al. (2006) (14).

2) MIC and MBC: Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were detected according to Batdorj et al. (2006)(14).

Results:

Lactic acid bacteria (LAB) are characterized as Gram-positive, short, single and paired square bacilli. The colonies on MRS agar were smooth and convex, catalase negative,

produced gas from glucose and NH₃ from arginine, grew at 45°C but poorly at 15°C, the isolates tolerated 0.3% and 10% bile, 0.3% and 0.4% phenol and 4% NaCl but not 8% NaCl, non-aerobic but aero tolerant, able to ferment carbohydrates included lactose, xylose, maltose, fructose, dextrose, galactose, raffinose, trehalose, mellibiose, sucrose, mannose for energy and lactic acid production but could not ferment L-arabinose, inuline, sodium gluconate, salicin, glucose amine, ribose, cellobiose and esculin. CFS of *L.fermentum* no. 5 was recovered with an increase in specific activity from 280-297.5 Au/mg after precipitation with ammonium sulphate as shown in table (1) Antimicrobial activity assay of *L.fermentum* CFS_s was done on 3 isolates of *E. faecium* and 3 isolates of *E. faecalis*. Among 9 *L. fermentum* CFS_s only no. 5 was able to inhibit the growth of all *Enterococcus* isolates. All of *L.fermentum* CFS concentrations showed closely related results and the most effective one was 1000 µg/ml as shown in table (2), and the most affected isolate of *E. faecalis* was no. 3 as shown in figure (1, 2), which its MIC was 64 µg/ml and MBC was 128 µg/ml as shown in table (3). The most affected isolate *E. faecium* was no. 1 as shown in figure (3, 4), which its MIC was 128 µg/ml and MBC was 256 µg/ml as shown in table (3). The results indicate that *L. fermentum* CFS in all concentrations (250, 500, 750, 1000) µg/ml possesses significant antibacterial activity against all *E. faecalis* and *E. faecium* isolates contrast with control $P < 0.05$ and the antibacterial activity of CFS in concentration 1000 µg/ml was significantly higher than other concentrations (250, 500, 750) µg/ml, $P < 0.05$.

Table (1): The purification strategy and results obtained for *L.fermentum* CFS no. 5.

Purification strategy	Volume (ml)	Activity	Total activity(Au)	Total protein(mg)	Specific Activity(Au/mg)	Yield (%)
Culture supernatant	28	18	504	1.8	280	100
Ammonium sulphate precipitate	7	34	238	0.8	297.5	47

Table (2): Inhibition zones of *L.fermentum* CFS no. 5 against *Enterococcus* isolates at concentrations (1000, 750, 500, 250) µg/ml.

Isolates	Inhibition zone (mm) [mean ± SD]				
	Concentration of <i>L. fermentum</i> CFS (µg/ml)				Control D. W.
	250	500	750	1000	
<i>E. faecalis</i>	19.33±1.82 p ₂ p ₁	21.33±2.1 p ₂ p ₁	27±0.86 p ₂ p ₁	32.66±2.11 p ₁	0±0
<i>E. faecium</i>	26.6±1.69 p ₂ p ₁	29±1.33 p ₂ p ₁	31.2±1.23 p ₂ p ₁	33.33±1.79 p ₁	0±0

p₁: probability compared to control $P < 0.05$

p₂: probability compared to 1000 µg/ml $P < 0.05$

Table (3): MIC and MBC of L.fermentum CFS no. 5 against Enterococcus isolates .

Enterococcus isolates	MIC	MBC
E. faecalis no. 1	512 µg/ml	1024 µg/ml
E. faecalis no. 2	128 µg/ml	256 µg/ml
E. faecalis no. 3	64 µg/ml	128 µg/ml
E. faecium no. 1	128 µg/ml	256 µg/ml
E. faeciumno. 2	256 µg/ml	512 µg/ml
E. faecium no. 3	256 µg/ml	512 µg/ml




Figure (1): Antibacterial activity of L.fermentum CFS no. 5 against E. faecalis no. 3 at concentrations (250, 500) µg/ml.




Figure (2): Antibacterial activity of L.fermentum CFS no. 5 against E. faecalis no. 3 at concentrations (750, 1000) µg/ml.




Figure (3): Antibacterial activity of L.fermentum CFS no. 5 against E. faecium no. 1 at concentrations (250, 500) µg/ml.




Figure (4): Antibacterial activity of L.fermentum CFS no. 5 against E. faecium no. 1 at concentrations (750, 1000) µg/ml.

Discussion:

To date, the main anti- infective properties described for lactobacilli are their ability to (i) adhere to surfaces and inhibit the adhesion of pathogens, (ii) inhibit the growth of pathogens, (iii) deplete nutrients otherwise available to pathogens, and (iv) modulate the host immune response and microenvironment, such that risk of infection is reduced (15). In vitro and clinical studies have provided evidence which supports the notion that lactobacilli may protect their hosts and keep them from acquiring urinary tract infection (16). Lactobacillus and Streptococcus species have been shown to be able to displace adhering uropathogenic E. faecalis strains from hydrophobic and hydrophilic substrata in a parallel – plate flow chamber , possibly through biosurfactant production ⁽¹⁶⁾, while in another study only a few lactobacilli were able to inhibit growth of E. faecalis (17). A ruminal isolate of L.fermentum produces an uncharacterized antimicrobial compound active against strains of Streptococcus bovis (18, 19). Viable LAB produces antibacterial material which inhibits growth of the pathogen (20, 21). The organic acids produced by some but not all strains of LAB such as benzoic acid, diacetyl, mevalonolactone, methylhydantoin and reuterin which maintain a competitive advantage (22).

In addition , several studies have revealed that certain LAB strains may also affect innate, humoral and cellular immune parameters as demonstrated by increased serum concentration of IgA , IgG and IgM (23), as well as killing of the cells by hydrogen peroxide and bacteriocin – like compound (24 , 25). The low pH makes organic acids liposoluble, allowing them to break through the cell membrane and reach the cytoplasm of pathogens (26). Bacteriocins are proteins or complexed proteins biologically active with antimicrobial action against other bacteria, principally closely related species (27). The cell wall of gram-positive bacteria allows passage of relatively large molecules, so that there is unlikely to be a requirement for bacteriocin receptors analogous to those in the outer membranes of gram negative cells. Anionic cell surface polymers like teichoic acid and lipoteichoic acid may be important in the initial interaction of cationic bacteriocins of Gram positive bacteria (28). The results of CFS of L. fermentum no. 5 agreed with findings of Mojgani et al. (2009) which reported that the increase in activity could be due to release of active monomers from bacteriocin complex (12). Bacteriocins may possess a bactericidal or bacteriostatic mode of action on sensitive cells, this distinction being greatly influenced by several factors such as bacteriocin dose and degree of purification, physiological

state of the indicator cells and experimental conditions (5).

In conclusion, *L. fermentum* CFS showed significant activity against both *Enterococcus* isolates and the concentration 1000 µg/ml has significantly higher effect than (250, 500, 750) µg/ml.

References:

- 1- Pascual, L.M., Daniel, M.B., Giordano, W., Pajaro, M.C. and Baberis, I.L. : Purification and partial characterization of novel bacteriocin L23 produced by *Lactobacillus fermentum* L23. *Curr. Microbiol.*, 2008, 56: 397-409.
- 2- Ruiz, F., Gerbaldo, G., Asurmendi, P., Pascual, L. and Barberis, I. : Antimicrobial activity inhibition of urogenital pathogens and synergistic interactions between *Lactobacillus* strains. *Curr. Microbiol.*, 2009, 59: 497-501.
- 3- Sartor, R.B. : Probiotics therapy of intestinal inflammation and infections. *Curr. Opin. Gastroenterol.*, 2005, 21: 44-50.
- 4- Reid, G. : In defense of probiotics. *Am. Soc. Microbiol. News*, 2000, 66: 261.
- 5- Cintas, L.M., Herranz, C., Hernandez, P.E., Casaus, M.P. and Nes, L.F. : Review : Bacteriocins of lactic acid bacteria. *Food Sci. Tech. Int.*, 2001, 7: 281-305.
- 6- Villoslada, F.L., Olivares, M., Sierra, S., Rodriguez, J.M., Boza, J. and Xaus, J. : Beneficial effects of probiotics bacteria isolated from breast milk. *British J. Nutr.*, 2007, 98(1): S96-S100.
- 7- Reid, G. and Burton, J. : Use of *Lactobacillus* to prevent infection by pathogenic bacteria. *Micro. Infec.*, 2002, 4: 319-24.
- 8- Strompfova, V., Marcinakova, M., Simonova, M., Matijasic, B.B. and Laukova, A. : Application of potential probiotic *Lactobacillus fermentum* A01 strain in healthy dogs. *Anaerobe*, 2006, 12: 75-9.
- 9- Parada, J.L., Caron, C.R., Medeiros, A.B.P. and Soccol, C.R. : Bacteriocins from lactic acid bacteria : Purification, properties and use as biopreservatives. *Braz. Arch. Biol. Technol.*, 2007, 50(3): 521-42 May.
- 10- Vuyst, L.D. and Leroy, F. : Bacteriocin from lactic acid bacteria : Production, purification and food applications. *J. Mol. Microbiol. Biotechnol.*, 2007, 13: 194-99.
- 11- Lowry, O., Rosebrough, N., Erba, A., et al. : Protein measurement with the folin phenol reagent. *J. Biol. Chem.*, 1951, 193: 267-75.
- 12- Mojtani, N., Sabiri, G. and Ashtiani, M. : Characterization of bacteriocins produced by *Lactobacillus brevis* NM24 and *Lactobacillus fermentum* NM332 isolated from green olives in Iran. *Int. J. Microbiol.*, 2009, 6(2).
- 13- Ghalfi, H., Benkerrom, N., Doguiet, D. and Bensaid, M. : Effectiveness of cell – adsorbed bacteriocin produced by *Lactobacillus curvatus* CWB1-B28 and selected essential oils to control *Listeria monocytogenes* in pork meat during cold storage. *Soci. Appl. Microbio.*, 2007: 268-73.
- 14- Batdorj, B., Dalgalarondo, M., Choieset, Y., Pedroche, J., Metro, F. and Prevost, H. : Purification and characterization of two bacteriocins produced by lactic acid bacteria isolated from Mongolian airag. *J. Appl. Microbiol.*, 2006, 101: 837-48.
- 15- Erickson, K.L. and Hubbard, N.E. : Probiotic immunomodulation in health and disease. *J. Nutr.*, 2000, 130(Suppl.) : S403-S09.
- 16- Velraeds, M.M.C., Mei, H.C., Reid, G. and Busscher, H.J. : Inhibition of initial adhesion of uropathogenic *Enterococcus faecalis* by biosurfactants from *Lactobacillus* isolates. *Appl. Environ. Microbiol.*, 1996 June: 1958-63.
- 17- Strus, M., Malinowska, M. and Heczko, P.B. : In vitro antagonistic effect of *Lactobacillus* on organisms associated with bacterial vaginosis. *J. Rep. Med.*, 2002, 47(1): 41-6.
- 18- Wells, J.E., Jrause, D.O., Callaway, T.R. and Russell, J.B. : A bacteriocin-mediated antagonism by ruminal *Lactobacilli* against *Streptococcus bovis*. *FEMS Microbiol. Ecol.*, 1997, 22: 237-43.
- 19- McAllister, T.A., Beauchemin, K.A., Alazeh, A.Y., Baah, J., Teather, R.M. and Standford, K. : Review: The use of direct fed microbials to mitigate pathogens and enhance production in cattle. *Can. J. Anim. Sci.*, 2011, 91: 193-211.
- 20- Kim, T.S., Hur, J.W., Yu, M.A., Cheigh, C.I., Kim, K.N., Hwang, J.K. and Pyun, Y.R. : Antagonism of *Helicobacter pylori* by bacteriocins of lactic acid bacteria. *J. Food Prot.*, 2003, 66: 3-12.
- 21- Lin, W.H., Yu, B., Lin, C.K., Hwang, W.Z. and Tsen, H.Y. : Immune effects of heat – killed multistrain of *Lactobacillus acidophilus* against *Salmonella typhimurium* invasion to mice. *J. Appl. Microbiol.*, 2007, 102: 22-31.
- 22- Brashears, M.M., Amezcua, A. and Jaroni, D. : Lactic acid bacteria and their uses in animal feeding to improve food safety. *Adv. Food Nutr. Res.*, 2005, 50: 1-31.
- 23- Haghighi, H.R., Gong, J., Gyles, C.L., Hayes, M.A., Zhou, H., Sanei, B., Chambers, J.R. and Sharif, S. : Probiotics stimulate production of natural antibodies in chickens. *Am. Soc. Microbiol.*, 2006, 13: 975-80.
- 24- Rishi, P., Preet, S. and Kaur, P. : Effect of *Lactobacillus plantarum* cell free extract and co-trimoxazole against *Salmonella typhimurium*. *J. Clin. Microbiol. Antimicrob.*, 2011, 109(4): 1349-60.
- 25- Reid, G., Bruce, A.W., Fraser, N., Heinemann, C., Owen, J. and Henning, B. : Oral probiotics can resolve urogenital infections. *FEMS Microbiol. Immunol.*, 2001, 49-52.
- 26- Haller, D., Colbus, H., Ganzle, M.G., Scherenbacher, P., Bode, C. and Hammes, W.P. : Metabolic and functional properties of lactic acid bacteria in the gastro-intestinal ecosystem : a comparative in vitro study between bacteria of intestinal and fermented food origin. *System. Appl. Microbiol.*, 2001, 24: 218-26.
- 27- Deraz, S.F., Karlsson, E.N., Hedstrom, M., Andersson, M.M. and Mattiasson, B. : Purification and characterization of acidocin D20079, a bacteriocin produced by *Lactobacillus acidophilus* DSM20079. *J. Biotechnol.*, 2005, 117: 343-54.
- 28- Jack, R.W., Tagg, J.R. and Ray, B. : Bacteriocins of Gram – positive bacteria. *Microbiol. Rev.*, 1995, 59: 171-200.